9. Michael Mahoney - Boston Scientific

2014 pay: $10.5 million
2015 pay: $11.5 million

Boston Scientific ($BSX) CEO Michael Mahoney led the company through a pivotal year in 2015, and took home more dollars for his hard work. Under Mahoney’s direction, the company eked out just over 1% of sales growth in 2015, but also notched key deals and partnerships to boost its offerings. Now, with recent progress in tow, Boston Scientific is planning a makeover.

The company recently revealed a global restructuring program “to support long-term growth and innovation” in “key growth markets,” Boston Scientific said in a statement. Mahoney will oversee layoffs, but he will also help create jobs in “areas of growth.”

"We are taking these steps to build on our momentum and meet the challenges of affordable health care around the globe," CEO Michael Mahoney said in the statement. The company “will continue to invest in strategic growth opportunities that enhance our reach, capabilities and efficiency to sustain our global competitiveness,” Mahoney said.

2015 laid the foundation for change. New approvals for its stroke-fighting Watchman device and Synergy partially bioresorbable stent added momentum. Mahoney said on Boston Scientific’s Q4 earnings call that the company is “uniquely positioned” with the stent, setting the stage for more progress in the months to come.

Mahoney also helped usher in deals in 2015. In November, Boston Scientific entered the radiology treatment market with its $70 million purchase of CeloNova.

Mahoney’s base salary was the lowest of the CEOs included on this list at $967,740. But the device helmsman’s pay also included $6.5 million in stock awards, $1.9 million in options and $1.8 million in non-equity incentives.

- here’s Boston Scientific’s proxy statement

For more:
Boston Scientific revamps itself to continue chasing long-term growth
Boston Scientific announces $200M option to purchase Israeli transcatheter mitral valve player
Boston Sci's stroke-fighting Watchman overcomes years of regulatory roadblocks, wins FDA approval

9. Michael Mahoney - Boston Scientific

Suggested Articles

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.